Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
MASSDEVICE ON CALL — Doctors are split when it comes to health care reform, according to a new survey from the Deloitte Center for Health Solutions.
Of the 501 doctors surveyed, 44 percent said the law was "a good start," while another 44 percent said health care reform was "a step in the wrong direction."
Overall, the doctors worried that the new system would increase access to government insurance programs without reducing costs, leaving fewer people uninsured but increasing emergency room wait times and lowering the total quality of care.
Stryker Corp. (NYSE:SYK) agreed to pay $150 million in up-front cash for Memometal Technologies SA, plus another $12 million in milestone payments.
Bruz, France-based Memometal makes implants for the extremities using shape memory alloys. The $162 million value of the deal is a 5.4x multiple of the $30 million the company posted to its top line last year.
MASSDEVICE ON CALL — Johnson & Johnson’s (NYSE:JNJ) may be looking at its proposed mega-merger with Synthes as a way to save its orthopedics business.
Under the terms of the merger agreement between the two companies, Forest Labs will pay $30 per share in cash, with additional milestone payments of up to $6 per share based on the commercial success of Clinical Data’s new antidepressant drug, Viibryd, according to the companies.
The CED Biotech/Life Science Conference in Raleigh, N.C. closed with the engaging and entertaining story of MedImmune LLC, the Maryland biotechnology company that was acquired by AstraZeneca plc (NYSE:AZN) for $15.6 billion in 2007.
AstraZeneca plc (NYSE:AZN) is shopping around its Astra Tech business.
The pharmaceutical giant said it’s begun a review of "strategic options" for its Swedish dental and medical device unit and hired JP Morgan Chase to help with the review.
Various news outlets reported that AstraZeneca is looking for about $2 billion for the business, which develops and markets dental implants and urological and surgical medical devices, according to the company.